The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center | Zendy

Stéphane Thibodeau | Zendy; Ioannis A. Voutsadakis | Zendy

Open Access

The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center

Author(s) -

Stéphane Thibodeau,

Ioannis A. Voutsadakis

Publication year - 2019

Publication title -

meme sağlığı dergisi/meme sağlığı dergisi

Language(s) - English

Resource type - Journals

eISSN - 1306-0953

pISSN - 1306-0945

DOI - 10.5152/ejbh.2019.4901

Subject(s) - medicine , cohort , breast cancer , oncology , cancer , chemotherapy , stage (stratigraphy) , estrogen receptor , adjuvant chemotherapy , paleontology , biology

To determine the influence of the Oncotype Dx assay on the treatment of patients with Estrogen Receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative, axillary lymph node-negative or micrometastatic carcinoma of the breast in a single cancer center. In addition, patients with intermediate Oncotype Dx recurrence scores were analyzed to assess the factors influencing therapeutic decisions for adjuvant chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research